FDA Clears Investigational New Drug Application for Novel BD2-Selective BET Inhibitor, VYN202
Phase Ia trial of VYN202, expected to begin this quarter, will enroll approximately 64 healthy participants.
The FDA has cleared an Investigational New Drug Application (IND) for VYNE Therapeutics' VYN202, an oral BD2-selective BET inhibitor. VYNE plans to initiate a first-in-human Phase Ia single ascending dose/multiple ascending dose (SAD/MAD) trial in healthy volunteers this quarter with top line results expected in the second half of 2024.1
“VYN202 is a highly selective and potent orally administered BET inhibitor that we believe has significant potential as a treatment option for autoimmune diseases. Clearance of the IND for VYN202 marks a major step forward in this effort,” David Domzalski, president and CEO of VYNE said in a press release. “We look forward to initiating the Phase Ia trial in the coming weeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.”
In October 2023, VYNE reported positive results from preclinical studies of VYN202 in models of psoriasis and rheumatoid arthritis.2
“We believe VYN202 has the potential to be the most potent and selective BET inhibitor in development and has consistently demonstrated its ability to improve signs and symptoms of disease with marked inhibition of key inflammatory cytokines implicated in the pathology of several chronic autoimmune diseases in preclinical models,” Domzalski said in an earlier press release. “These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis. We look forward to advancing these programs into the clinic next year and updating investors on our progress.”
The Phase Ia clinical trial of VYN202 is a double-blind, placebo-controlled study in healthy volunteers and consists of SAD and MAD components. It is expected to enroll approximately 64 healthy adult participants, who will be split into five SAD and three MAD cohorts to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.
Looking forward, if this portion of the trial is successfully completed, VYNE plans to initiate Phase Ib trials in subjects with moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis, with top line results anticipated in the second half of 2025.
References
1. VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor. Press release. May 6, 2024. Accessed May 7, 2024. https://vynetherapeutics.com/press-releases/vyne-therapeutics-announces-fda-clearance-of-ind-application-for-vyn202-a-novel-bd2-selective-bet-inhibitor/
2. VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202. Press release. October 30, 2023. Accessed May 7, 2024. https://vynetherapeutics.com/press-releases/vyne-therapeutics-reports-positive-results-from-preclinical-models-for-oral-bd2-selective-bet-inhibitor-vyn202/
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
